TERN NASDAQ
Terns Pharmaceuticals, Inc.
1W: +0.0%
1M: +0.7%
3M: +40.2%
YTD: +32.0%
1Y: +1647.5%
3Y: +310.5%
5Y: +161.1%
$52.95
Last traded 2026-05-15 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$110M
-8.1% ▼
Net Income
-$96M
-8.3% ▼
EPS (Diluted)
$-1.03
+8.0% ▲
EBITDA
-$110M
-9.1% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $1M | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | -100.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $1M | $0 | $0 | $0 | $0 |
| Gross Margin | 100.0% | — | — | — | — |
| R&D Expenses | $31M | $40M | $63M | $70M | $78M |
| SG&A Expenses | $20M | $22M | $39M | $32M | $32M |
| Operating Expenses | $51M | $62M | $103M | $102M | $110M |
| Operating Income | -$50M | -$62M | -$103M | -$102M | -$110M |
| Operating Margin | -4986.0% | — | — | — | — |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | -$50M | -$60M | -$90M | -$89M | -$96M |
| Tax Expense | $508K | $358K | $239K | $260K | $581K |
| Net Income | -$50M | -$60M | -$90M | -$89M | -$96M |
| Net Margin | -5015.8% | — | — | — | — |
| EPS (Diluted) | $-1.98 | $-1.67 | $-1.27 | $-1.12 | $-1.03 |
| EBITDA | -$49M | -$61M | -$102M | -$101M | -$110M |
| Shares Outstanding | 25M | 36M | 71M | 80M | 93M |